Labiotech.eu

North america sequencing ultima genomics biotech investment

In Depth 27 Jun 2022

The biggest US biotech investments in May 2022

The DNA sequencing newcomer Ultima Genomics won the crown for the biggest U.S private biotech investment in May 2022. Other top fundraising firms are developing gene and cell therapies in addition to cultured leather and omics-based diagnostics. The headliner private biotech investment in the US in May 2022 went to the Californian firm Ultima Genomics. […]

June 27, 2022 - 3 minutesmins - By Jonathan Smith

More News! 24 Jun 2022

Gurnet Point Capital and Patient Square Capital buy Radius Health for $890M

Global pharmaceutical company, Radius Health Inc, announced this week (June 23) that it has entered into a definitive agreement to be bought out by Gurnet Point Capital and Patient Square Capital in a transaction valued at approximately $890 million. Radius Health is a company focused on addressing unmet medical needs in the areas of bone […]

June 24, 2022 - 3 minutesmins - By Liza Laws

News and Trends 24 Jun 2022

Stramsen Biotech to look at 11 plant-based drug candidates

Houston-based biotechnology firm Stramsen Biotech Inc. has announced 11 drug candidates for clinical development. Kefas Mugittu, co-CEO, made the announcement of the plant-based medical candidates. The company said the drugs are safe, effective and currently in use in different countries. The drug candidates are: SBX 1052, which controls/prevents enlargement of the prostate glands; SBX1968, which […]

June 24, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 24 Jun 2022

Study reveals progress for those with hepatitis B

A clinical-stage biopharma company has announced its study of product VTP-300 for use in patients with hepatitis B has resulted in positive safety and efficacy data. Vaccitech plc deals with novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, cancer, and autoimmune diseases. The updated analysis includes 39 patients with at least […]

June 24, 2022 - 3 minutesmins - By Liza Laws

News and Trends 24 Jun 2022

Covid and malaria vaccines on track for mass production in Rwanda

Construction of the first African messenger RNA (mRNA) manufacturing facility has started in Africa. This means Biopharmaceutical New Technologies (BioNTech) SE is a step closer to producing mRNA vaccines that teach human cells how to make a protein that will trigger an immune response inside the body. The company is a next generation immunotherapy company […]

June 24, 2022 - 3 minutesmins - By Liza Laws

News and Trends 24 Jun 2022

Second dairy cellular agtech incubator program Mylkcubator opens

Pascual, a Spanish manufacturer of dairy products and beverages, has launched Mylkcubator 2.0, the second edition of its global incubation program for cellular agriculture technologies in the dairy industry. The initiative has been launched from the group’s Corporate Venture unit, Pascual Innoventures, in collaboration with Eatable Adventures, a global foodtech accelerator. Mylkcubator 2.0 will last […]

June 24, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 24 Jun 2022

Beyond Biotech podcast 2: Asabys, Asebio, MOA Foodtech

This week’s podcast is dedicated to Spain. We have conversations with bioindustry association AseBio’s CEO, Ion Arocena; Clara Campàs, managing partner and co-founder of venture capital company Asabys, and Susana Sánchez Gómez, co-founder and chief scientific officer at MOA Foodtech. AseBio, the Spanish Bioindustry Association, brings together and represents the interests of companies, associations, foundations, […]

June 24, 2022

News and Trends 23 Jun 2022

Evaxion Biotech picks candidate for lung cancer trial

A clinical-stage biotech company that specializes in developing AI-driven immunotherapies has chosen its product candidate for an upcoming clinical trial for patients with advanced lung cancer. Evaxion Biotech selected EVX-03 within its DNA technology platform to target a new indication based on what it said are very encouraging results from pre-clinical studies. EVX-03 is optimized […]

June 23, 2022 - 2 minutesmins - By Liza Laws

News and Trends 23 Jun 2022

Antheia gets funding to build biomanufacturing plant

Antheia, a U.S. synthetic biology company enabling next-generation plant-inspired medicines, has announced $40 million in venture debt financing from Oxford Finance LLC and Silicon Valley Bank. The company also unveiled plans to construct a new pilot scale biomanufacturing facility. The financing will support Antheia’s expansion with a 14,700 square-foot pilot plant located next to Antheia’s […]

June 23, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 23 Jun 2022

Osivax gets €10M influenza vaccine grant

A grant of €10 million ($10.5 million) has been secured by pharmaceutical company Osivax to support a vaccine against influenza. The biopharma company develops vaccines to provide broad-spectrum protection against highly mutating infectious viruses and diseases. It announced today (June 23) that it has secured the funds from Bpifrance to support the further clinical development […]

June 23, 2022 - 2 minutesmins - By Liza Laws

News and Trends 23 Jun 2022

Scancell to produce and clinically validate T cell redirecting bispecific antibodies

Scancell Holdings plc, which develops immunotherapies for the treatment of cancer and infectious disease, has announced it will develop its GlyMab antibodies into T cell redirecting bispecific (TCB) antibodies and take them into the clinic. The UK company said this is a promising new therapeutic approach to treat cancer. TCB antibodies have dual-binding specificity, which […]

June 23, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 23 Jun 2022

Krystal Biotech looks for FDA approval for dystrophic epidermolysis bullosa treatment

U.S. gene therapy company Krystal Biotech, Inc, has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of B-VEC (beremagene geperpavec) for the treatment of patients with dystrophic epidermolysis bullosa (DEB). B-VEC is an investigational non-invasive, topical gene therapy designed to treat DEB at the molecular level by […]

June 23, 2022 - 3 minutesmins - By Jim Cornall

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The biggest US biotech investments in May 2022

Gurnet Point Capital and Patient Square Capital buy Radius Health for $890M

Stramsen Biotech to look at 11 plant-based drug candidates

Study reveals progress for those with hepatitis B

Covid and malaria vaccines on track for mass production in Rwanda

Second dairy cellular agtech incubator program Mylkcubator opens

Beyond Biotech podcast 2: Asabys, Asebio, MOA Foodtech

Evaxion Biotech picks candidate for lung cancer trial

Antheia gets funding to build biomanufacturing plant

Osivax gets €10M influenza vaccine grant

Scancell to produce and clinically validate T cell redirecting bispecific antibodies

Krystal Biotech looks for FDA approval for dystrophic epidermolysis bullosa treatment

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!